037. Could somatostatin enhance the outcomes of chemotherapeutic treatment in small-cell carcinoma (SCLC)?
The Pan Hellenic Congress Abstracts

037. Could somatostatin enhance the outcomes of chemotherapeutic treatment in small-cell carcinoma (SCLC)?

Kalliopi Domvri1, Dimitrios Bougiouklis2, Paul Zarogoulidis1, Konstantinos Porpodis1, Manolis Xristoforidis3, Alexandra Liaka1, Ellada Eleutheriadou1, Ioannis Organtzis1, George Kyriazis1, Bianka Malecki4, Konstantinos Zarogoulidis1

1Asthma Clinic, Pulmonary Department, Aristotle University of Thessaloniki, George Papanikolaou Hospital, Exochi, Thessaloniki, Greece; 2Gene and Cell Therapy Center, Hematology - BMT Unit, “G. Papanikolaou” Hospital, Thessaloniki, Greece; 3Surgical Department “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; 4Medical University of Warsaw, Żwirki i Wigury 61, Warszawa, Poland

Objective: Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an invaluable drug target for the pharmacological management of pituitary adenomas and neuroendocrine tumors. Furthermore, somatostatin (SST) receptors (SSTR1, 2A and B, 3, 4 and 5) belong to the G protein coupled receptor family and are overexpressed in tumors. Since, human small-cell lung cancer overexpresses somatostatin receptors (SSTR), they could be legitimate targets for treating small-cell carcinoma (SCLC). The aim of this study was the evaluation of cytotoxicity of somatostatin in combination with several anticancer drugs in HTB-175 cell line (Small Cell Lung Cancer Cell line that expresses neuron specific enolase) which was purchased from ATCC LGC Standards.

Methods: Docetaxel, Paclitaxel, Carboplatin, Cisplatin, Etoposide, Gemzar, Navelbine, Fluorouracil, Farmorubicin are the chemotherapeutic drugs that we used for the combination before and after adding somatostatin in cell culture. At indicated time-point, 48 h after the combination, cell viability and apoptosis were measured with Annexin V staining by flow cytometry.

Results: Flow cytometry showed that Docetaxel, Paclitaxel, Gemzar and Cisplatin induced apoptosis more when they were added before somatostatin, whereas etoposide induced apoptosis more after somatostatin treatment. Navelbine alone or in combination with somatostatin showed no differences in apoptosis. Farmorubicin showed equally toxicity in all combinations. Fluorouracil and Carboplatin induced apoptosis more when added alone in HTB-175 cell line. However, increased apoptosis was also observed when Carboplatin was administered before somatostatin in higher concentrations.

Conclusions: Our results indicated that depending on the drug, somatostatin treatment before or after chemotherapeutic drugs increased apoptosis in small cell lung cancer cells. We suggest that long acting somatostatin analogues could be used as additive and maintenance therapy in combination to antineoplastic agents in SCLC patients.

Keywords: Lung cancer; somatostatin; targeted therapy

doi: 10.3978/j.issn.2072-1439.2015.AB037

Cite this abstract as: Domvri K, Bougiouklis D, Zarogoulidis P, Porpodis K, Xristoforidis M, Liaka A, Eleutheriadou E, Organtzis I, Kyriazis G, Malecki B, Zarogoulidis K. Could somatostatin enhance the outcomes of chemotherapeutic treatment in small-cell carcinoma (SCLC)? J Thorac Dis 2015;7(S1):AB037. doi: 10.3978/j.issn.2072-1439.2015.AB037

Article Options

Download Citation